<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534754</url>
  </required_header>
  <id_info>
    <org_study_id>2006-00064322-25</org_study_id>
    <nct_id>NCT01534754</nct_id>
  </id_info>
  <brief_title>Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon</brief_title>
  <official_title>Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: a Double-blind, Double-dummy, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Cristo Re</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Cristo Re</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double blind, double-dummy, parallel groups,
      placebo-controlled trial was conducted in a population of patients suffering from symptomatic
      uncomplicated diverticular disease in order to investigate which is the best treatment in
      preventing relapses of the disease.

      Patients were randomly divided in double-blind fashion in one of the following groups:

      Group A. Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei
      placebo, 1 sachet/day for 10 days/month;

      Group B. Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800
      placebo, 2 tablets/day for 10 days/month;

      Group C. Active mesalazine 800 ng, 2 tablets/day plus Active Lactobacillus casei, 1
      sachet/day for 10 days/month;

      Group D. Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1
      sachet/day for 10 days/month.

      The main objective was to assess the safety and the efficacy of mesalazine and/or
      Lactobacillus casei in maintaining remission of symptomatic uncomplicated diverticular
      disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients maintaining remission of symptomatic uncomplicated diverticular disease of the colon</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the treatments</measure>
    <time_frame>one year</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of severity of diverticulosis on number of patients maintaining remission of symptomatic diverticular disease of the colon</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant diseases</measure>
    <time_frame>one year</time_frame>
    <description>Influence of concomitant diseases on remission maintenance</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Diverticular Disease of the Colon</condition>
  <arm_group>
    <arm_group_label>Mesalazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus casei</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalazine plus Lactobacillus casei</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine plus Lactobacillus casei</intervention_name>
    <description>Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.</description>
    <arm_group_label>Mesalazine plus Lactobacillus casei</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine placebo plus Lactobacillus casei placebo</intervention_name>
    <description>Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine 800 mg</intervention_name>
    <description>Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.</description>
    <arm_group_label>Mesalazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus casei</intervention_name>
    <description>Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.</description>
    <arm_group_label>Lactobacillus casei</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of diverticular disease diagnosed for the first time or established by
             previous colonoscopy

          -  symptomatic episode of uncomplicated diverticular disease no more than 4 weeks prior
             to study entry

          -  patients who have given their free and informed consent.

        Exclusion Criteria:

          -  acute diverticulitis (both complicated and uncomplicated)

          -  diverticular colitis

          -  active or recent peptic ulcer

          -  chronic renal insufficiency

          -  allergy to salicylates

          -  patients with intended or ascertained pregnancy, lactation

          -  women of childbearing age not using contraceptives

          -  lactulose-lactitol use in the two weeks before the enrolment and during the study

          -  presence of diverticulitis complications (fistulas, abscesses, and/or stenoses)

          -  use of probiotic preparations either prescribed or over-the counter within two weeks
             prior to study entry

          -  inability to give a valid informed consent or to properly follow the protocol

          -  patients with active malignancy of any type, or history of a malignancy (patients with
             a history of other malignancies that have been surgically removed and who have no
             evidence of recurrence for at least five years before study enrolment were also
             acceptable)

          -  recent history or suspicion of alcohol abuse or drug addiction

          -  any severe pathology that can interfere with the treatment or the clinical or
             instrumental tests of the trial

          -  use of NSAIDS for one week before and throughout the study period (only paracetamol
             was permitted).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Brandimarte, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Gastroenterology, Hospital &quot;Cristo Re&quot; - Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Bonomo</name>
      <address>
        <city>Andria</city>
        <state>Bari</state>
        <zip>70031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Padre Pio&quot;</name>
      <address>
        <city>Vasto</city>
        <state>Chieti</state>
        <zip>66054</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Humanitas&quot;</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Hospital</name>
      <address>
        <city>Popoli</city>
        <state>Pescara</state>
        <zip>65026</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;S. Giuseppe&quot;</name>
      <address>
        <city>Albano</city>
        <state>Rome</state>
        <zip>00041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;G.B. Grassi&quot;</name>
      <address>
        <city>Ostia</city>
        <state>Rome</state>
        <zip>00122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;P. Colombo&quot;</name>
      <address>
        <city>Velletri</city>
        <state>Rome</state>
        <zip>00049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Policlinico</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Pulgiese-Ciaccio&quot;</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Ospedali Riuniti&quot;</name>
      <address>
        <city>Foggia</city>
        <zip>71122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;S. Maria Goretti&quot;</name>
      <address>
        <city>Latina</city>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsitla Policlinico</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;S. Eugenio&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Cristo Re&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2012</study_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Cristo Re</investigator_affiliation>
    <investigator_full_name>Giovanni Brandimarte</investigator_full_name>
    <investigator_title>MD; PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diverticulum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

